Australia's most trusted
source of pharma news
Posted 22 November 2021 AM
In a win for Australians with the rare and potentially deadly condition, hereditary angioedema, Health Minister Greg Hunt has awarded Takeda's Takhzyro a PBS berth from December 1.
It's been a long haul for Takhzyro which first went before PBAC in July 2019. It was not recommended at that meeting and a second submission a year later in July 2020 was deferred. In a case of third time lucky, the therapy was finally ticked after PBAC's July meeting this year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.